However, we have previously shown that the CSF-based AD-biomarker profile of these individuals improves post-MMKD, as indicated by an increase in Aβ42 levels (in both MCI and CN) and a decrease in tau (only in MCI)20. Here, MAPT is linked to Alzheimer disease.